High-yield points
- OPGs are low-grade, with high survival (about 98% at 5 years in one series). Treat to protect vision and the hypothalamus .
- NF1: both optic nerves, more indolent. Sporadic: chiasm and hypothalamus, more progressions .
- First line: carboplatin and vincristine.
- 5-year EFS about 39% in non-NF1 vs 69% in NF1, in low-grade glioma overall (not OPG-specific) .
- Starting under age 1 predicts progression .
- Visual acuity is the key endpoint, and it correlates poorly with imaging. About a third of children with NF1 OPG improve after chemotherapy .
- Selumetinib in recurrent sporadic OPG: 2-year PFS 78% .
- Surgery is selective: biopsy, CSF diversion, or debulking for mass effect.
- Debulking was associated with worse visual and endocrine outcomes than biopsy in one small series ; any surgery was associated with endocrine–metabolic dysfunction in infants .
- Infants: diencephalic syndrome, hypothalamic involvement, surgery and radiotherapy all raise endocrine and metabolic risk .
Landmark papers
- COG A9952 (Ater et al., J Clin Oncol 2012): a randomized trial of carboplatin–vincristine vs TPCV (274 children under 10 with low-grade glioma). 5-year EFS was 39% vs 52% (P = .10 by stratified log-rank; a cure-model analysis favored TPCV) .
- Fisher et al., Neuro Oncol 2012: multicenter NF1 OPG visual outcomes after chemotherapy. Visual acuity improved in 32%, was stable in 40% and declined in 28%, and correlated poorly with imaging, which made vision the key endpoint .
- PBTC-029 selumetinib (Fangusaro et al., Neuro Oncol 2021): recurrent sporadic optic–hypothalamic glioma (25 patients). 2-year PFS was 78%, and vision improved in 21% of 19 evaluable patients .
Optic pathway gliomas (OPGs) are low-grade gliomas, mostly pilocytic astrocytomas. They arise along the optic nerves, chiasm, tracts and radiations, often extending into the hypothalamus (optic–hypothalamic glioma) .
- Survival is high: 5-year overall survival was about 98% in one series .
- The real burden is functional:
- vision;
- endocrine and metabolic problems;
- neurobehavioral problems.
- The modern approach :
- chemotherapy or targeted therapy first;
- surgery for selected indications;
- avoid radiotherapy in young children.
- NF1 vs sporadic: NF1-associated OPGs behave differently and are covered in Neurofibromatosis. This chapter emphasizes the sporadic tumors that neurosurgeons more often see.
Classification and patterns
- Modified Dodge classification (applied to 72 patients in an international trial) :
- more detailed than the original 1958 Dodge system, and proposed for clinical trials;
- NF1 tumors more often involved both optic nerves and multiple sites;
- sporadic (NF1-negative) tumors more often involved the central chiasm and hypothalamus.
- Histology: pilocytic astrocytoma predominates; pilomyxoid astrocytoma and ganglioglioma also occur .
- Molecular testing (BRAF and others) guides targeted therapy .
Presentation
- Visual loss, often unnoticed in young children, with nystagmus, strabismus or optic atrophy.
- Hydrocephalus from a large chiasmatic–hypothalamic mass blocking the foramina of Monro (see caveats).
- Endocrine: precocious puberty, growth hormone deficiency, and diencephalic syndrome (failure to thrive despite normal intake) in infants.
- Infants and very young children (90 children under 3, followed 9.5 years) :
- 57.8% developed endocrine–metabolic dysfunction, mostly with hypothalamic involvement;
- a diencephalic syndrome presentation raised it (85.2% vs 46%);
- radiotherapy (OR 16.2) and surgery (OR 4.8) were also associated with it;
- obesity occurred in 25%, and neurobehavioral deficits in more than half.
Medical treatment
- First-line chemotherapy: carboplatin and vincristine (CV).
- COG A9952 randomized CV against TPCV in children under 10 with progressive or residual low-grade glioma (274 patients) :
- 5-year EFS 39% with CV vs 52% with TPCV: not significant by stratified log-rank (P = .10), though a cure-model analysis favored TPCV (P = .007);
- overall survival 86%;
- younger age and tumor size over 3 cm² predicted worse outcome;
- differences in toxicity may guide the choice.
- NF1 vs non-NF1 on CV (low-grade glioma at any site, not OPG-specific) :
- 5-year EFS 69% vs 39%;
- NF1 independently predicted better EFS.
- National cohort (136 treated children, 112 of whom received systemic therapy; 92% of those got first-line CV) :
- PFS 61.8% at 3 years and 48.4% at 5 years;
- sporadic tumors needed more treatments, with more second progressions;
- starting CV under 1 year of age was the sole independent predictor of progression.
- Vision is the outcome that matters.
- NF1 OPG after chemotherapy (88 children) :
- visual acuity improved in 32%, was stable in 40% and declined in 28%;
- radiographic and visual outcomes correlated poorly, so imaging response alone shouldn't define success.
- MEK inhibition (selumetinib) for recurrent sporadic optic–hypothalamic glioma (25 patients, median 4 prior therapies) :
- partial response 24%, stable disease 56%;
- 2-year PFS 78%;
- visual acuity (19 evaluable) improved in 21% and was stable in 68%.
Role of surgery
- Biopsy: consider it when the imaging is atypical, or when molecular data will guide targeted therapy. Typical NF1 OPGs don't need tissue (see caveats).
- Debulking: reserve it for:
- mass effect or hydrocephalus;
- a large exophytic component;
- progression despite medical therapy.
- Aim: decompression, not gross total resection of the chiasm or hypothalamus.
- Biopsy vs debulking (26 children, single center) :
- biopsy was associated with better visual and endocrine outcomes than debulking;
- all patients needed adjuvant therapy;
- 5-year overall survival was 98%.
- Hydrocephalus:
- CSF diversion (shunt, or endoscopic septostomy for a trapped ventricle);
- biopsy at the same time when tissue is needed (see caveats).
- Isolated optic nerve tumor with a blind, proptotic eye: resection of the nerve can be considered (see caveats).
Related topics
- Neurofibromatosis: NF1-associated OPG.
- Pilocytic Astrocytoma: the usual histology.
- Supratentorial Low-Grade Glioma: other pediatric low-grade gliomas.
- Craniopharyngioma: the other suprasellar tumor affecting vision and the hypothalamus.
References
- Taylor T, Jaspan T, Milano G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 2008;81(970):761–766. doi:10.1259/bjr/65246351. PMID 18796556. verified
- Del Baldo G, Cacchione A, Dell'Anna VA, et al. Rethinking the management of optic pathway gliomas: a single center experience. Front Surg 2022;9:890875. doi:10.3389/fsurg.2022.890875. PMID 35784925. verified
- Bennebroek CAM, van Zwol J, Montauban van Swijndregt MC, et al. A retrospective, nationwide, multicenter study on diagnosis and treatment outcome of pediatric optic pathway/hypothalamic gliomas including analysis of risk factors for progression after systemic anticancer therapy. Cancers (Basel) 2025;17(5):716. doi:10.3390/cancers17050716. PMID 40075564. verified
- Picariello S, Cerbone M, D'Arco F, et al. A 40-year cohort study of evolving hypothalamic dysfunction in infants and young children (<3 years) with optic pathway gliomas. Cancers (Basel) 2022;14(3):747. doi:10.3390/cancers14030747. PMID 35159015. verified
- Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol 2012;30(21):2641–2647. doi:10.1200/JCO.2011.36.6054. PMID 22665535. verified
- Ater JL, Xia C, Mazewski CM, et al. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children's Oncology Group. Cancer 2016;122(12):1928–1936. doi:10.1002/cncr.29987. PMID 27061921. verified
- Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 2012;14(6):790–797. doi:10.1093/neuonc/nos076. PMID 22474213. verified
- Fangusaro J, Onar-Thomas A, Poussaint TY, et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol 2021;23(10):1777–1788. doi:10.1093/neuonc/noab047. PMID 33631016. verified
Verification (2026-11-18):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- the clinical presentations (visual signs, hydrocephalus, precocious puberty, the diencephalic syndrome definition);
- avoiding radiotherapy;
- indications for biopsy and debulking;
- CSF diversion strategies;
- optic nerve resection for a blind eye;
- no biopsy needed for typical NF1 OPG.
- Reference 2 is a small single-center series, and its biopsy versus debulking comparison is unadjusted.
- References 5 and 6 included low-grade gliomas at any site (reference 5: children under 10), not only OPG.
- In reference 3, sporadic status itself was not an independent risk factor for progression after CV; age under 1 year was.
- The figure is an original schematic.